Basilea Pharmaceutica AG

Swiss commercial‑stage biotech specializing in severe bacterial & fungal infections. Portfolio includes approved Cresemba and Zevtera, plus a strong pipeline—fosmanogepix, ceftibuten‑ledaborbactam, BAL2062—and strategic collaborations for growth.

Headquarters: Switzerland (CHE)

Basilea Pharmaceutica AG Logo
Company Profile
  • Employees: 180
  • HQ: Allschwil
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
BSLN Basilea Pharmaceutica AG
Cap: 0.7B | P/E: 10.6
EQUITY EBS CHF CH0011432447 Active
📈
Home Login